

Global Diabetes Drug Market & Pipeline Insight 2015

<https://marketpublishers.com/r/GF3ACECD611EN.html>

Date: April 2015

Pages: 1100

Price: US\$ 2,400.00 (Single User License)

ID: GF3ACECD611EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criterias set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.

Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn't seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.

Several molecules belonging to different classes like carbohydrate digestion inhibitors, sulphonyl urea, insulin sensitizers and others are being screened for their effects on

diabetes. They have to prove their candidature by providing better safety and efficacy profiles than existing diabetes drugs. Rigorous clinical trials would be required to prove their pharmacological worthiness for effectively treating diabetes patients. These molecules are known to have cytotoxicity due to which they may have side effects but by modulating its design such problems could be overcome by investigators. On the other hand, these molecules are easy to produce and offer higher cost effectiveness due to which pharmaceutical companies have become interested in their research and development. In coming years, more molecules of these types are expected to enter in global market which would be affordable by large number of patients belonging to different socio-economic groups.

Besides screening of novel molecules, emphasis on discovering different pathways have been given by investigators for developing diabetes drugs with higher safety and efficacy profiles. Insulin pathway is one of the most studied pathways that have been widely targeted by investigators to maintain blood glucose levels. Diabetes drugs that target cellular receptors have been made which works at molecular levels because they have higher control over insulin regulation. Some drug molecules increase the glucose uptake in cells to decrease blood glucose levels. On the other hand, there are diabetes drugs that act on the gastrointestinal tract and prevent the carbohydrate digestion in the body. Investigators have developed many methods to control diabetes and several innovative mechanisms are being studied to come forth with better products. As a result, more products will be launched due to which their market penetration is expected to increase in coming years.

Diabetes Indication in Report:

Diabetic Neuropathies

Diabetic Nephropathies

Diabetes Mellitus

Type 1 Diabetes Mellitus

Type 2 Diabetes Mellitus

Diabetic Foot Ulcer

Diabetic Macular Oedema

Diabetic Gastroparesis

Diabetic Retinopathy

Diabetes Insipidus

Prediabetic State

'Global Diabetes Drug Market & Pipeline Insight 2015' Report Highlight:

Global Diabetes Drug Market Overview

Global Diabetic Drug Clinical Pipeline by Company & Phase

Global Diabetic Drug Clinical Pipeline: 817 Drugs

Majority in Preclinical Phase: 205 Drugs

Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs

Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs

Diabetic Nephropathies Drugs in Pipeline: 41 Drugs

Marketed Diabetic Drugs: 99 Drugs

Contents

1. INTRODUCTION TO DIABETES

2. DIABETES DRUG MECHANISM

3. GLOBAL DIABETES DRUG MARKET OVERVIEW

3.1 Current Market Scenario

3.2 Global Diabetes Drug Pipeline Overview

4. GLOBAL DIABETES DRUG MARKET DYNAMICS

4.1 Favorable Market Parameters

4.2 Development & Commercialization Challenges

5. GLOBAL DIABETES DRUG MARKET FUTURE PROSPECTS

6. DIABETIC NEUROPATHIES DRUG CLINICAL PIPELINE BY COMPANY & PHASE

6.1 Research to till Registered

6.2 Marketed Drug Clinical Insight

7. DIABETIC NEPHROPATHIES DRUG CLINICAL PIPELINE BY COMPANY & PHASE

7.1 Research to till Registered

7.2 Marketed Drug Clinical Insight

8. DIABETES MELLITUS DRUG CLINICAL PIPELINE BY COMPANY & PHASE

8.1 Phase Research to till Registered

8.2 Marketed Drug Clinical Insight

9. TYPE 1 DIABETES MELLITUS DRUG CLINICAL PIPELINE BY COMPANY & PHASE

9.1 Research to till Registered

9.2 Marketed Drug Clinical Insight

10. TYPE 2 DIABETES MELLITUS DRUG CLINICAL PIPELINE BY COMPANY & PHASE

10.1 Research to till Registered

10.2 Marketed Drug Clinical Insight

11. DIABETIC FOOT ULCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE

11.1 Research to till Phase-III

11.2 Marketed Drug Clinical Insight

12. DIABETIC MACULAR OEDEMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

12.1 Research to till Registered

12.2 Marketed Drug Clinical Insight

13. DIABETIC GASTROPARESIS DRUG CLINICAL PIPELINE BY COMPANY & PHASE

13.1 Preclinical to till Phase-III

13.2 Marketed Drug Clinical Insight

14. DIABETIC RETINOPATHY DRUG CLINICAL PIPELINE BY COMPANY & PHASE

14.1 Research to till Phase-III

15. PREDIABETIC STATE DRUG CLINICAL PIPELINE BY COMPANY & PHASE

15.1 Phase-II

16. DIABETES DRUG CLINICAL PIPELINE BY COMPANY & PHASE

16.1 Research to till Registered

16.2 Marketed Drug Clinical Insight

17. COMPETITIVE LANDSCAPE

- 17.1 AstraZeneca
- 17.2 Boehringer Ingelheim
- 17.3 Eli Lilly
- 17.4 GalaxoSmithKline
- 17.5 Johnson & Johnson
- 17.6 MannKind Corporation
- 17.7 Merck
- 17.8 Novartis
- 17.9 Pfizer
- 17.10 Sanofi

COMPANIES

AstraZeneca, Boehringer Ingelheim, Eli Lilly, GalaxoSmithKline, Johnson & Johnson, MannKind Corporation, Merck, Novartis, Pfizer, Sanofi

I would like to order

Product name: Global Diabetes Drug Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/GF3ACECD611EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF3ACECD611EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970